Soligenix, Inc. (SNGX) stock
SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.28−0.01 (-2.67%)
Close on Nov 17, 2026Market cap $6.11MP/E –Yield –
Soligenix EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Soligenix's EPS for the twelve months ending Sep 30, 2024 was -$7.80. For fiscal 2025 it was -$2.14. The highest annual figure on record is -$2.14 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.14 | – |
| FY2024 | Dec 31, 2024 | -$4.98 | – |
| FY2023 | Dec 31, 2023 | -$12.66 | – |
| FY2022 | Dec 31, 2022 | -$76.96 | – |
| FY2021 | Dec 31, 2021 | -$75.04 | – |
| FY2020 | Dec 31, 2020 | -$153.60 | – |
| FY2019 | Dec 31, 2019 | -$115.20 | – |
| FY2018 | Dec 31, 2018 | -$163.20 | – |
| FY2017 | Dec 31, 2017 | -$278.40 | – |
| FY2016 | Dec 31, 2016 | -$321.60 | – |
| FY2015 | Dec 31, 2015 | -$720.00 | – |
| FY2014 | Dec 31, 2014 | -$1032.00 | – |
| FY2013 | Dec 31, 2013 | -$1560.00 | – |
| FY2012 | Dec 31, 2012 | -$888.00 | – |
| FY2011 | Dec 31, 2011 | -$528.00 | – |
| FY2010 | Dec 31, 2010 | -$1752.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.12 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.28 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.58 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.82 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.97 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.78 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.31 | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.91 | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.80 | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.56 | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.56 | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.76 | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.82 | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.40 | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.28 | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.32 | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.32 | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.60 | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.00 | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.40 | – |
| Q4 FY2020 | Dec 31, 2020 | -$44.28 | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.40 | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$76.80 | – |
| Q1 FY2019 | Mar 31, 2019 | -$21.60 | – |
| Q4 FY2018 | Dec 31, 2018 | -$42.02 | – |
| Q3 FY2018 | Sep 30, 2018 | -$26.40 | – |
| Q2 FY2018 | Jun 30, 2018 | -$43.20 | – |
| Q1 FY2018 | Mar 31, 2018 | -$64.80 | – |
| Q4 FY2017 | Dec 31, 2017 | -$66.28 | – |
| Q3 FY2017 | Sep 30, 2017 | -$40.80 | – |
| Q2 FY2017 | Jun 30, 2017 | -$98.40 | – |
| Q1 FY2017 | Mar 31, 2017 | -$76.80 | – |
| Q4 FY2016 | Dec 31, 2016 | -$18.45 | – |
| Q3 FY2016 | Sep 30, 2016 | -$117.60 | – |
| Q2 FY2016 | Jun 30, 2016 | -$45.60 | – |
| Q1 FY2016 | Mar 31, 2016 | -$141.60 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?